Public Release: 

American College of Chest Physicians unveils new lung cancer screening guidelines at CHEST 2017

Experts to reveal key recommendations and updates to screening evidence

American College of Chest Physicians

TORONTO (October 26, 2017) - Each year, more people die of lung cancer than of colon, breast and prostate cancers combined, and low-dose CT (LDCT) screening for lung cancer has become a standard practice mostly due to the results of the National Lung Cancer Screening Trial. Evidence continues to evolve, in turn informing the benefits and risks of LDCT in clinical practice.

Lung cancer experts and authors of the manuscript submitted to the journal CHEST® -- Screening for Lung Cancer: CHEST Guideline and Expert Panel Report -- and will present the updated evidence to provide recommendations at CHEST 2017.

Key recommendations and shifts from previous guidelines include:

  • For asymptomatic smokers and former smokers age 55 to 77 who have smoked 30 pack-years or more and either continue to smoke or have quit within the past 15 years, we suggest that annual screening with low-dose CT should be offered.

  • For asymptomatic smokers and former smokers who do not meet the smoking and age criteria in Recommendation #1 but are deemed to be at high risk of having/developing lung cancer based on clinical risk prediction calculators, we suggest that low-dose CT screening should not be routinely performed.

  • For individuals who have accumulated fewer than 30 pack-years of smoking or are younger than age 55 or older than age 77, or have quit smoking more than 15 years ago, and do not have a high risk of having/developing lung cancer based on clinical risk prediction calculators, we recommend that low-dose CT screening should not be performed.

  • For individuals with comorbidities that adversely influence their ability to tolerate the evaluation of screen-detected findings, or tolerate treatment of an early stage screen-detected lung cancer, or that substantially limit their life expectancy, we recommend that low-dose CT screening should not be performed.

"This guideline differs from our previous guideline as we went beyond discussing harms and benefits," said Peter Mazzone, M.D., F.C.C.P., guideline chair. "We addressed implementation of low-dose CT screening, including who to screen, how to identify appropriate patients for screening, how to conduct a shared-decision-making visit, how to perform LDCT and how to manage abnormal findings."

"The potential benefit of cancer screening to reduce the number of cancer-related deaths must be balanced with potential harms of screening," said Gerard Silvestri, M.D., F.C.C.P., guideline panelist and CHEST immediate past president. "Current evidence suggests that even within groups at high risk of developing a cancer, only a small fraction of those screened will benefit, while everyone screened is exposed to potential harms including physical and psychosocial consequences of identifying and subsequently evaluating a screen-detected nodule, radiation exposure, overdiagnosis and overtreatment. For this reason, our recommendations for screening have evolved to be even more selective and specifically target those highest risk populations. The evidence currently does not support widespread adoption of lung cancer screening outside of those patients described in our recommendations."

Further results from the guidelines will be shared at the CHEST Annual Meeting 2017 in Toronto on Wednesday, November 1, 11 a.m. to 12:15 p.m. at the Metro Toronto Convention Centre, room 701A. The session will also be live streamed on Facebook Live by CHEST. The recommendation summary along with remarks for each recommendation and abstract can be viewed on the website of the American College of Chest Physicians, and forthcoming complete manuscript will be published in the journal CHEST.


CHEST 2017 is the 83rd annual meeting of the American College of Chest Physicians, held October 28 to November 1, 2017, in Toronto, Ontario. The American College of Chest Physicians, publisher of the journal CHEST®, is the global leader in advancing best patient outcomes through innovative chest medicine education, clinical research and team-based care. Its mission is to champion the prevention, diagnosis and treatment of chest diseases through education, communication and research. It serves as an essential connection to clinical knowledge and resources for its 19,000+ members from around the world who provide patient care in pulmonary, critical care and sleep medicine. For more information about CHEST 2017, visit, or follow CHEST meeting hashtag, #CHEST2017, on social media.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.